Lifileucel

Lifileucel, sold under the brand name Amtagvi, is an adoptive T cell therapy used to treat melanoma, and is a personalized cancer immunotherapy made from a patient's own tumor-infiltrating lymphocytes. Tumor tissue is surgically removed, the patient's T cells that had infiltrated the tumor are isolated and expanded in a laboratory, and the expanded cells are reinfused as a single dose meant to strengthen the immune system's fight against the cancer. It is indicated for adults with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and, if the patient carries a BRAF V600 mutation, prior treatment with a BRAF inhibitor with or without a MEK inhibitor. It received FDA approval in February 2024, becoming the first tumor-derived T cell immunotherapy approved by the FDA.